Our partnerships
Cancer Research Horizons partners across the fields of academia, industry, drug discovery and investors.
Under the terms of the agreement, which is on a fee-for-service basis and is for 6 months’ duration, Sareum will provide computational chemistry expertise to support several of CRT’s therapeutic discovery programmes in cancer. Financial terms of the agreement were not disclosed.
Commenting on the announcement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said: “We are delighted that we have been chosen by Cancer Research Technology to provide these drug discovery services and we look forward to making a valuable contribution to their development programmes.”
Commenting on the announcement, CRT’s Head of Medicinal Chemistry, Dr Tony Raynham, said: “Importantly, Sareum’s core capabilities in computational chemistry will support CRT’s medicinal chemistry department in the development of drug candidates arising from the research activities of our parent charity Cancer Research UK and our other prestigious international partners.”
